ORKA vs. GLPG, AAPG, IMCR, DYN, KNSA, GPCR, NRIX, ARQT, ARDX, and INDV
Should you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include Galapagos (GLPG), Ascentage Pharma Group International (AAPG), Immunocore (IMCR), Dyne Therapeutics (DYN), Kiniksa Pharmaceuticals (KNSA), Structure Therapeutics (GPCR), Nurix Therapeutics (NRIX), Arcutis Biotherapeutics (ARQT), Ardelyx (ARDX), and Indivior (INDV). These companies are all part of the "pharmaceutical products" industry.
Oruka Therapeutics vs.
Galapagos (NASDAQ:GLPG) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, community ranking, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.
Galapagos has higher revenue and earnings than Oruka Therapeutics.
In the previous week, Galapagos had 9 more articles in the media than Oruka Therapeutics. MarketBeat recorded 12 mentions for Galapagos and 3 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 0.83 beat Galapagos' score of 0.14 indicating that Oruka Therapeutics is being referred to more favorably in the news media.
Galapagos received 450 more outperform votes than Oruka Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Oruka Therapeutics an outperform vote while only 63.84% of users gave Galapagos an outperform vote.
32.5% of Galapagos shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Comparatively, 22.7% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Galapagos' return on equity of 0.00% beat Oruka Therapeutics' return on equity.
Galapagos currently has a consensus target price of $26.75, suggesting a potential upside of 0.04%. Oruka Therapeutics has a consensus target price of $39.86, suggesting a potential upside of 261.68%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Oruka Therapeutics is more favorable than Galapagos.
Galapagos has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.
Summary
Oruka Therapeutics beats Galapagos on 9 of the 15 factors compared between the two stocks.
Get Oruka Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oruka Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ORKA) was last updated on 2/22/2025 by MarketBeat.com Staff
Free ORKA Stock Alerts